Teva Pharmaceutical Industries Ltd.

Israeli pharmaceutical company

TEVA Tel Aviv Stock Exchange · home listing Tel Aviv Stock Exchange TEVA NYSE ISIN IL0006290147 SEC CIK 818686 LEI 549300BAFGM4RC74ZJ94
Follow Teva Pharmaceutical Industries Ltd. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $4.4B −1.9% vs same quarter last year
Net income $233M −46.2% vs same quarter last year
EPS, diluted $0.20 −45.9% vs same quarter last year
Operating cash flow $241M −34.7% vs same quarter last year
Revenue by quarter
$4.2B
$3.9B
$4.2B
$4.5B
$1.5B
$4B
$4.1B
$4.4B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$20B−$10B$0$10B$20B$30BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$17.3B$1.4B
FY24$16.5B−$1.6B
FY23$15.8B−$559M
FY22$14.9B−$2.4B
FY21$15.9B$417M
FY20$16.7B−$4B
FY19$16.9B−$999M
FY18$18.3B−$2.2B
FY17$21.9B−$16.3B
FY16$21.9B$329M
FY15$19.7B$1.6B
FY14$20.3B$3.1B
FY13$20.3B$1.3B
FY12$20.3B$2B
FY11$18.3B$2.8B
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2551.8%12.5%8.2%
FY2448.7%−1.8%−9.9%
FY2348.2%2.7%−3.5%
FY2246.7%−14.7%−16.4%
FY2147.8%10.8%2.6%
FY2046.4%−21.4%−24%
FY1944.6%−2.6%−5.9%
FY1845.4%−9%−11.8%
FY1748.6%−80%−74.4%
FY1653.2%9.8%1.5%
FY1557.8%17.1%8.1%
FY1454.5%19.5%15.1%
FY1352.7%8.1%6.2%
FY1252.4%10.9%9.7%
FY1152%17%15.1%
Free cash flowOperating cash flow minus capital expenditure
$0$2B$4B$6BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$1.1B
FY24$749M
FY23$842M
FY22$1B
FY21$236M
FY20$638M
FY19$223M
FY18$1.8B
FY17$1.4B
FY16$3B
FY15$4.8B
FY14$4.2B
FY13$2.2B
FY12$3.5B
FY11$3.1B
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
$0$1B$2B$3BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearDividendsBuybacks
FY25--
FY24--
FY23--
FY22--
FY21--
FY20--
FY19--
FY18$12M-
FY17$901M$0
FY16$1.3B$0
FY15$1.2B$439M
FY14$1.2B$500M
FY13$1.1B$497M
FY12$855M$1.2B
FY11$800M$899M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Teva Pharmaceutical Industries Ltd.
  • Healthcare median
−100%−75%−50%−25%0%25%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearTeva Pharmaceutical Industries Ltd.Healthcare median
FY258.2%−30.6%
FY24−9.9%−47%
FY23−3.5%−58%
FY22−16.4%−80.4%
FY212.6%−71.9%
FY20−24%−62.2%
FY19−5.9%−46.3%
FY18−11.8%−49.6%
FY17−74.4%−45.9%
FY161.5%−36%
FY158.1%−38.4%
FY1415.1%−35.5%
FY136.2%−37.1%
FY129.7%−29.1%
FY1115.1%−27.9%